Taiwan-based pharmaceutical company Bora Pharmaceuticals Co., Ltd. has taken a significant step toward expanding its global investor base. The company has announced that its shares will now be eligible for trading on the U.S. OTCQX Market, a move aimed at increasing visibility and accessibility for American investors. Bora Pharma will trade under the symbol “BORAY” through a Level-1 American Depositary Receipt (ADR) program.
This development is being seen as an important milestone in the company’s international growth strategy.
What Is the Latest News?
On January 7, 2026, OTC Markets Group officially confirmed that Bora Pharmaceuticals has been admitted to the OTCQX Market, the highest tier of the U.S. over-the-counter markets. OTCQX is known for its strict financial reporting and corporate governance standards, and only companies that meet these requirements are allowed to trade on it.
With this listing, U.S. investors can now buy and sell Bora Pharma shares more easily, without the complexities of investing directly in foreign exchanges.
Company Introduction: Bora Pharmaceuticals
Founded in 2007, Bora Pharmaceuticals Co., Ltd. is a Taiwan-based pharmaceutical company already listed on the Taiwan Stock Exchange.
The company operates mainly in two key areas:
- CDMO (Contract Development and Manufacturing Organization): Developing and manufacturing medicines for other pharmaceutical companies
- Commercial Pharmaceuticals: Producing and selling its own branded and generic drugs
Bora Pharma focuses on high-quality manufacturing, advanced technology, and serving global healthcare markets.
Why Is OTCQX Trading Important?
Being traded on OTCQX is considered a mark of credibility for international companies.
- Companies must maintain transparent financial disclosures
- Strong corporate governance practices are mandatory
Bora Pharma’s inclusion on OTCQX signals that it meets internationally recognized standards, which can help build confidence among global investors.
Strong U.S. Presence Already in Place
Bora Pharma already has a solid footprint in the United States. The company previously acquired Upsher-Smith Laboratories, a U.S.-based generic drug manufacturer, significantly strengthening its manufacturing and distribution capabilities in the American market.
In addition to the U.S., Bora Pharma operates facilities in Taiwan, the United States, and Canada, and supplies pharmaceutical products to more than 100 countries worldwide.
Revenue Profile and Global Business
A key strength of Bora Pharmaceuticals is its international revenue base. More than 90% of the company’s revenue comes from outside Taiwan, highlighting its position as a truly global pharmaceutical player.
Growing demand for CDMO services and the company’s presence in developed markets such as the U.S. and Canada are expected to support long-term growth.
What Does This Mean for Investors?
The start of trading on OTCQX could:
- Improve share liquidity
- Increase participation from U.S. and global investors
- Enhance the company’s global profile and valuation visibility
While OTCQX is not as large as Nasdaq or the NYSE, it is often seen as a strong entry platform for international companies looking to access U.S. capital markets.
Outcome
Bora Pharmaceuticals’ entry into the U.S. OTCQX Market marks an important step not only for the company but also for Taiwan’s pharmaceutical industry. It reflects Bora’s ambition to position itself as a global pharmaceutical and CDMO leader, rather than just a regional player.
Going forward, investor interest from the U.S. market and continued expansion in North America will be key factors to watch in Bora Pharma’s growth story.
Source: bora globenewswire
